Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.50 |
| ▸ | PI4KA | P42356 | 3/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.43 |
| ▸ | ADCY5 | O95622 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | AHCY | P23526 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4272738 | 0.85 | CDK1 (0.51) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL2911275 | 0.76 | CYP3A4 (0.43) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL4273041 | 0.75 | HDAC6 (0.39) | ALDH1A1 | |
| SCHEMBL10835443 | 0.70 | ADORA2A (0.56) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL3005457 | 0.70 | ADORA2A (0.48) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL3005461 | 0.70 | ADORA2A (0.48) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL3293432 | 0.68 | FGFR1 (0.47) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL2495370 | 0.68 | ADORA2A (0.69) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL22558037 | 0.68 | ADORA2A (0.69) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1924594 | 0.68 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605147-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2009-10-20 | — | — | US | claimed |
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | CHO DONG-GYU | 2006-12-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | ADORA2A 119/4885ADORA1 174/4885PI4KA 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.